News Report | May 27, 2022
FDA Clears Neuronetics TMS For OCD
On May 10, 2022, Neuronetics, Inc., announced it received Food and Drug Administration (FDA) clearance for its transcranial magnetic stimulation (TMS) system, NeuroStar Advanced Therapy, as an adjunct treatment for adults with obsessive-compulsive disorder (OCD). This is the second use indication for the NeuroStar TMS system. The FDA granted the first in October 2008 for use as primary treatment for adults with major depressive disorder (MDD) who have not responded to antidepressant medication.
NeuroStar's TMS is a non-invasive outpatient treatment that delivers targeted magnetic pulses to stimulate neurons in the area of the brain that controls mood . . .